Caso Clínico

Cutaneous mastocytosis in the adult: what lies beneath

Liliana Torres, Francisco Bento Soares, Diana Pereira Anjos, Mari Mesquita
Centro Hospitalar do Tâmega e Sousa. Portugal

Abstract
Mastocytosis is a disorder characterized by clonal mast cell proliferation and accumulation within various organs, most commonly, the skin. Adult-onset mastocytosis is highly suggestive of a systemic involvement and the cases limited to the skin are uncommon. The authors report a 61-year-old male with pruritus associated with hyperpigmented maculopapular skin lesions and a positive Darier’s sign. The skin biopsy revealed spindle mast cells infiltrations. The bone marrow study was normal. He started on H1 antihistamines with significant clinical improvement.

Keywords: Mastocytosis. Mast cells. Darier’s sign.

Introduction
Mastocytosis is a rare heterogeneous group of hematopoietic disorders characterized by increased accumulation of mast cells in one or more organs. The most frequently involved are the skin but bone marrow, gastrointestinal tract, liver, spleen and lymph nodes may also be implicated. The incidence is estimated in 1 in 1000 to 8000 patients. Adults who develop mastocytosis often have a systemic disease form at the time of diagnosis; the cutaneous subtypes account for less than 5% of cases.

Case Report
A 61-year-old male, without any known diseases or medication, present with generalized pruritic rash for the past 2 years. He denied any other symptoms. The physical examination showed hyperpigmented maculopapular lesions on the trunk and limbs (Figures 1a and 1b). Darier’s sign was positive. The rest of the physical exam was irrelevant. Apart from an erythrocyte sedimentation rate of 11mm/h, complete blood cell count, blood glucose, renal and hepatic functions, sodium, potassium, total and ionized calcium were within normal ranges. Chest radiography, abdominal ultrasound and bone densitometry had no alterations. Histopathology of the skin showed perivascular infiltration of the upper dermis consisting of moderate mononuclear inflammatory infiltrates with increased number of spindle mast cells. Bone marrow aspirate was normocellular. He started with oral cetirizine 5mg bid and loratadine 10mg id with significant clinical improvement. He didn’t report for regular check-ups.

Discussion
In 1869, Nettleship and Tay described a rare form of urticaria with pigmented papular lesions, later termed as urticaria pigmentosa by Sangster in 1878. After mast cells were described by Paul Ehrlich in 1879, the disease was classified as mastocytosis. Until 1949, it was believed that mastocytosis was only a cutaneous disease, but then Ellis described involvement of visceral organs as well.

Figure 1A. Hyperpigmented maculae on the back

Figure 1B. A close-up of the back lesions
Human mast cells originate from pluripotent cells (CD34+) in the bone marrow and migrate, through the bloodstream, to a specific tissue where they differentiate into two subgroups based on their structures, biochemistry and functions: mucosal and connective tissue mast cells.

Release of mast cell-derived mediators, such as histamine, prostaglandins, leukotrienes, tumor necrosis factor, interleukins and platelet activating factors may lead to a variety of symptoms and signs such as erythema, edema, pruritus, urticaria, bronchoconstriction, headache, flushing, nasal stuffiness, dizziness, tachycardia, hypotension, syncope, anorexia, nausea, vomiting, increased gastric acidity, abdominal pain and diarrhea. Classic signs such as Darier’s sign and dermographism are due to the local release of these mediators.

Although a number of classification schemes have been given for mast cell disease, the WHO classification seems to be more practical and useful for characterizing the disorder. It was divided into two main types, cutaneous and systemic, as described in Table 1, and classified into different subtypes.

Cutaneous mastocytosis describes forms of mastocytosis limited to the skin, in the absence of involvement of other organs. Skin lesions may be subdivided into urticaria pigmentosa, maculopapular cutaneous mastocytosis, diffuse cutaneous mastocytosis and mastocytoma of the skin.

Systemic mastocytosis involves an extracutaneous site, most commonly the bone marrow and in some cases, the gastrointestinal (GI) tract. The subtypes include indolent systemic mastocytosis, systemic mastocytosis with an associated hematologic non-mast cell lineage disease, aggressive systemic mastocytosis, mast cell leukemia, mast cell sarcoma and extracutaneous mastocytoma.

The aim of mastocytosis therapy is to remove or reduce the symptoms. Treatment involves combining H1 antihistamines (for pruritus, flushing, urticaria) and H2 antihistamines (to reduce acidity, diarrhea and other GI manifestations). Daily oral mast cell-stabilisers mitigate onset and frequency of cutaneous and GI symptoms. Systemic corticosteroids are used in ascites, malabsorption, and severe skin disease (bullous). PUVA therapy is used for persistent urticaria pigmentosa in adults for cosmetic improvement.

Cutaneous mastocytosis that develops in adulthood tends to persist over time but has a benign prognosis. Rare cases of progression to aggressive forms such as mast cell sarcoma and mast cell leukemia have been reported and are associated with a poor outcome.

To detect disease progression a yearly monitoring is recommended with serum tryptase levels (which reflect mast cell burden); complete blood cell count (to rule out hematologic malignancies); serum chemistry panel to monitor liver involvement and electrolyte imbalances and bone densitometry (yearly if documented osteopenia or osteoporosis and every 3 years if normal bone density).

REFERENCES